IMUX Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

03
Price $7.96
Market Cap (MRQ) $109M
P/E -0.9
EPS $-0.62
52W Range $1–$17

IMUX Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

04
range
bars

Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.

Stock splits 2
Ex-date Split Type
April 27, 2026 1-for-10 Reverse
April 15, 2019 1-for-40 Reverse

10-Year Performance Revenue, net income, margins and EPS trends

06
EPS$-0.62
2020-12-31 → 2025-12-31
Free Cash Flow·
2016-12-31 → 2024-12-31
Valuation & Ratios 07–12

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric 5Y trend IMUX 5Y avg Peer Median Verdict
P/E -0.95Y avg ≈-1.1 ≈-1.1 · ·
P/B (MRQ) 0.95Y avg ≈2.4 ≈2.4 2.4 Undervalued
Price / FCF (TTM) -1.25Y avg ≈-1.5 ≈-1.5 · ·
Price / Cash Flow (TTM) -1.25Y avg ≈-1.5 ≈-1.5 · ·
Price / Tangible Book 4.95Y avg ≈2.6 ≈2.6 · ·

Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.

value · ≈ 5Y avg · industry median · verdict relative to median

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

14
Avg Surprise 7.8%
Next Report Nov 11, 2026
PeriodReportEPS ActualEPS EstSurprise
June 30, 2026 Aug 5, 2026 $-0.80 $-1.22 34.3%
March 31, 2026 May 13, 2026 $-1.08 $-0.93 -16.0%
Dec. 31, 2025 $-0.70 $-0.96 27.1%
Sept. 30, 2025 $-1.30 $-1.71 23.9%
June 30, 2025 $-2.00 $-1.68 -18.8%
March 31, 2025 $-0.25 $-0.24 -3.6%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

15
Income Statement 14
Metric Trend 202520242023202220212020201920182017201620152014
R&D Expense $82M$80M$83M$71M$61M$39M$23M$10M$39M$30M$40M$39M
SG&A Expense $21M$18M$16M$15M$13M$10M$15M$2M$13M$11M$12M$11M
Operating Expenses $103M$98M$99M$119M$92M$49M$37M$12M$53M$41M$52M$50M
Operating Income $-103M$-98M$-99M$-119M$-92M$-49M$-37M$-12M$-53M$-41M$-52M$-50M
Interest Income $1M$3M$3M$1M$66.0K$58.0K$107.0K$521.0K$650.0K$284.0K$58.0K$19.0K
Other Non-op $5M$-1M$3M$-2M$-1M$5M$2M$456.0K$-73.0K$13.0K$39.0K$56.0K
Pretax Income ·······$-41M$-52M$-41M$-52M$-48M
Income Tax $0···········
Net Income $-97M$-101M$-94M$-120M$-93M$-44M$-35M$-12M$-52M$-41M$-52M$-48M
EPS (Basic) $-0.62$-1.00$-2.11$-3.78$-3.93$-2.81······
EPS (Diluted) $-0.62$-1.00$-2.11$-3.78$-3.93$-2.81······
Shares (Basic) 155,688,030100,174,76644,320,05031,819,00623,652,77915,663,826······
Shares (Diluted) 155,688,030100,174,76644,320,05031,819,00623,652,77915,663,826······
EBITDA ·$-98M$-99M$-119M$-92M$-49M$-37M$-41M·$-39M$-51M$-49M
Balance Sheet 23
Metric Trend 202520242023202220212020201920182017201620152014
Cash & Equivalents $15M$36M$47M$107M$87M$127M$29M$13M$57M$60M$83M$102M
Prepaid Expense $7M$4M$6M$9M$18M$6M$3M$259.0K$1M$1M$1M$986.0K
Other Current Assets $831.0K$1M$1M$1M$1M$1M$796.0K$68.0K····
Current Assets $23M$39M$53M$126M$105M$134M$32M$13M$58M$61M$85M$105M
PP&E (Net) $608.0K$545.0K$466.0K$294.0K$152.0K$203.0K$80.0K$40.0K$2M$3M$4M$3M
PP&E (Gross) ·······$11M$12M$12M$12M$10M
Accum. Depreciation ·······$11M$10M$10M$8M$7M
Goodwill ···$0$33M$33M$33M$0····
Other Non-current Assets ··$0$43.0K$42.0K$42.0K$42.0K$0$108.0K$58.0K$184.0K$198.0K
Total Assets $24M$41M$54M$128M$139M$168M$66M$13M$60M$64M$89M$108M
Accounts Payable $10M$8M$5M$4M$4M$4M$2M$1M$1M$780.0K$1M$1M
Accrued Liabilities $19M$13M$19M$8M$7M$4M$3M$416.0K$9M$5M$5M$9M
Current Liabilities $31M$22M$25M$13M$11M$8M$7M$2M$10M$5M$7M$10M
Capital Leases $107.0K$264.0K$639.0K$992.0K$584.0K$679.0K$520.0K$41.0K$59.0K···
Other Non-current Liabilities ·······$0·$99.0K$101.0K$241.0K
Total Liabilities $31M$22M$25M$14M$12M$9M$8M$2M····
Common Stock $9.0K$8.0K$4.0K$4.0K$3.0K$2.0K$1.0K$0$4.0K$3.0K$3.0K$2.0K
Paid-in Capital $599M$526M$436M$428M$324M$267M$120M$56.0K$346M$302M$285M$248M
Retained Earnings $-609M$-511M$-411M$-317M$-197M$-104M$-60M$-25M$-296M$-244M$-203M$-151M
AOCI $3M$4M$4M$3M$-252.0K$-4M$-1M$-819.0K$78.0K$83.0K$80.0K$89.0K
Stockholders' Equity $-7M$18M$29M$114M$127M$159M$58M$-26M$-13M$58M$82M$98M
Liabilities + Equity $24M$41M$54M$128M$139M$168M$66M$13M$60M$64M$89M$108M
Shares Outstanding 12,038,2639,015,08745,177,73039,307,28626,335,41821,168,24010,744,806846,95342,368,86432,143,47530,473,08323,982,786
Cash Flow 12
Metric Trend 202520242023202220212020201920182017201620152014
D&A $168.0K$134.0K$111.0K$77.0K$85.0K$39.0K$50.0K$15.0K$998.0K$2M$1M$1M
Stock-based Comp $9M$9M$7M$8M$6M$3M$7M$0$5M$5M$4M$3M
Deferred Tax ·$0$0$0$0$0$0$0····
Other Non-cash ·$7M$16M$47M$4M$-5M$-174.0K$-6M·$-1M$-3M$3M
Operating Cash Flow $-86M$-85M$-71M$-65M$-83M$-46M$-29M$-10M$-40M$-36M$-50M$-41M
CapEx $161.0K$264.0K$334.0K$112.0K$67.0K$146.0K$55.0K$32.0K$685.0K$556.0K$2M$1M
Investing Cash Flow $-161.0K$-264.0K$9M$-10M$-67.0K$-146.0K$11M$-32.0K$-678.0K$-21.0K··
Stock Issued $0$191.0K$853.0K···$0$19M$38M$12M$32M$88M
Net Stock Activity ·$191.0K····$0$0·$12M$32M$88M
Financing Cash Flow $66M$75M$1M$96M$43M$144M$35M$19M$38M$12M··
Net Change in Cash $-20M$-11M$-60M$20M$-41M$98M$16M$9M$-3M$-23M$-19M$64M
Free Cash Flow ·$-85M$-71M$-65M$-83M$-46M$-29M$-44M·$-36M$-52M$-42M
Profitability 2
Metric Trend 202520242023202220212020201920182017201620152014
ROA ·-211.2%-102.8%-90.2%-60.6%-37.6%-88.1%-110.1%·-53.5%-52.8%-61.6%
ROE ·-337.0%-242.1%-108.2%-68.2%-27.4%-58.8%990.7%·-58.2%-57.8%-180.2%
Liquidity & Solvency 2
Metric Trend 202520242023202220212020201920182017201620152014
Current Ratio ·1.82.19.69.215.94.65.7·11.212.810.2
Quick Ratio ·1.61.98.27.615.24.25.3·10.912.59.9
Per Share 6
Metric Trend 202520242023202220212020201920182017201620152014
Book Value / Share ·$0.20$0.64$2.89$4.83$7.50$5.43$0.29·$1.82$2.70$4.07
Cash Flow / Share ·$-0.85$-1.60$-2.05$-3.52·······
Cash / Share ·$0.40$1.03$2.72$3.30$6.02$2.73$0.31·$1.87$2.74$4.26
Dividend / Share $0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00····
Dividend Paid / Share $0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00····
EPS (TTM) $-0.62$-1.00$-2.11$-3.78$-3.93$-2.81······
Valuation (TTM) 8
Metric Trend 202520242023202220212020201920182017201620152014
Net Income TTM $-97M$-101M$-94M$-120M$-93M$-44M$-35M$-12M$-52M$-41M$-52M$-48M
Market Cap ·$90M$68M$55M$252M$324M$104M$315M·$5.59B$14.04B$23.92B
P/E -0.9-1.0-0.7-0.4-2.4-5.4······
P/B ·4.92.30.52.02.01.825.4·95.7170.6245.1
P / Tangible Book ·4.92.30.52.72.6······
P / Cash Flow ·-1.1-1.0-0.8-3.0-7.0-3.7-7.3·-156.3-281.1-585.8
P / FCF ·-1.1-1.0-0.8-3.0-7.0-3.6-7.2·-153.9-268.5-566.3
Earnings Yield -116.1%-100.0%-140.7%-270.0%-41.1%-18.4%······

Most recent period on the left · null values shown as ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

16
Metric 2025-12-312024-12-312023-12-312022-12-312021-12-31
Net Income $-97M $-101M $-94M $-120M $-93M
Diluted EPS $-0.62 $-1.00 $-2.11 $-3.78 $-3.93

Institutional owners (13F) 3 filers · $2.7M total · As of March 31, 2026

17

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Holders 3
Value held $2.7M
New positions 38
Exited positions 18
Institutional activity — Q1 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
38 (+29 vs prior Q) 18 (+9 vs prior Q) 22 (+4 vs prior Q) 7 (-4 vs prior Q) +12.9M

Compared to Q4 2025. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution Value Shares % of tracked 13F Type
VANGUARD GROUP INC $2,680,860 5,020,337 99.27% Shares
WOLVERINE TRADING, LLC $10,239 10,953 0.38% Shares
CWM, LLC $9,593 8,642 0.36% Shares

Activists & 5%+ owners 12 positions

18

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer Filed Stake Status Purpose Filing
BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF PARTNERS L P/IL, BVF INC/IL, LAMPERT MARK N, R. Thorvald Nagel Feb. 20, 2026 9.99% Initial filing Passive investment SEC
LSP V Coöperatieve U.A, LSP V Management B.V. ×2 filings Feb. 24, 2023 · Initial filing · SEC
Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person Feb. 13, 2023 · Initial filing · SEC
Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person March 15, 2022 · Initial filing · SEC
Undisclosed reporting person Sept. 21, 2020 · Initial filing · SEC
Undisclosed reporting person June 18, 2020 · Initial filing · SEC
Undisclosed reporting person April 23, 2019 · Initial filing · SEC
Undisclosed reporting person April 22, 2019 · Initial filing · SEC
Undisclosed reporting person April 22, 2019 · Initial filing · SEC
Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person April 22, 2019 · Initial filing · SEC
Undisclosed reporting person April 22, 2019 · Initial filing · SEC
Muneer A. Satter (2) ×3 filings Sept. 18, 2018 · Initial filing · SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Company insiders 40 insiders · 9 officers · 13 directors

19
Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
Erik Lundgren Chief Executive Officer May 22, 2026 A · 0 0 $0
Glenn Whaley Chief Financial Officer June 29, 2026 A 95,510 0 0 $0
Sanjay S Patel Chief Financial Officer July 22, 2019 A · 0 0 $0
Jason Tardio President and COO June 29, 2026 A 12,512 0 0 $0
Manfred Groeppel Chief Operating Officer March 1, 2021 A 278,830 0 0 $0
Michael A. Panzara Chief Medical Officer April 24, 2026 A · 0 0 $0
Andreas Muehler Chief Medical Officer July 16, 2025 A 297,986 0 0 $0
Duane Nash Executive Chairman July 16, 2025 A 36,032 0 0 $0
Andrea Loewen Vice President, Regulatory Affairs and Quality Assurance May 13, 2016 A · 0 0 $0
Robert Thorvald Nagel Director Sept. 16, 2026 A · 0 0 $0
Simona Skerjanec Director July 5, 2026 A · 0 0 $0
Richard Alan Rudick Director July 5, 2026 A 230,375 0 0 $0
Joerg Neermann Director July 5, 2026 A 200,000 0 0 $0
Jon Congleton Director July 5, 2026 A · 0 0 $0
Barclay A Phillips Director July 5, 2026 A · 0 0 $0
Daniel Vitt Director June 29, 2026 A 29,000 0 0 $0
Michael W Bonney Director June 29, 2026 A · 0 0 $0
Tamar D Howson Director June 29, 2026 A · 0 0 $0
Monika Maria Toernsen Director June 5, 2025 A · 0 0 $0
Jan Van Den Bossche Director June 15, 2022 A · 0 0 $0
Vincent Ossipow Director June 15, 2022 A · 0 0 $0
Elena Ridloff · Aug. 6, 2026 A · 0 0 $0
Michael V. Swanson · Jan. 11, 2019 A · 0 0 $0
Robert A. Ashley · Jan. 11, 2019 A 2,000 0 0 $0
Russell J. Cox · Jan. 11, 2019 A · 0 0 $0
John Michael Dunn · Jan. 11, 2019 A 11,885 0 0 $0
Errol R. Halperin · Sept. 25, 2018 S 0 0 0 $0
Jean Jacques Bienaime · Sept. 24, 2018 S 18,500 0 0 $0
Douglas Evan Godshall · Sept. 19, 2018 S 0 0 0 $0
Satter Muneer A · Sept. 17, 2018 S 0 0 0 $0
Faheem Hasnain · Sept. 13, 2018 S 4,500 0 0 $0
Cheryl Cohen · Sept. 12, 2018 S 0 0 0 $0
Aron Stern · July 1, 2018 A 6,380 0 0 $0
Andrew Henry · June 9, 2018 A · 0 0 $0
Richard M Murawski · June 9, 2018 A · 0 0 $0
Michael J. Millis · May 23, 2018 A 17,680 0 0 $0
Lowell Sears · May 23, 2018 A 58,572 0 0 $0
Terence E. Winters · June 14, 2017 P 194,966 0 0 $0
Philip M Croxford · May 23, 2017 A 25,091 0 0 $0
Randolph C Steer · May 23, 2017 A 1,549 0 0 $0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

ETF ownership Held by 4 ETFs

20

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund Weight Units As of Source
QQQS · Invesco Exchange-Traded Fund Trust … 0.28% 7,546 SH Oct. 2, 2026 Daily
IWC · iShares Trust 0.04% 46,946 SH Sept. 11, 2026 Daily
VXF · VANGUARD INDEX FUNDS 0.00% 159,248 SH Aug. 19, 2026 Daily
VTI · VANGUARD INDEX FUNDS 0.00% 399,088 SH Aug. 19, 2026 Daily

IMUX Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

21
rating · 18 analysts BUY
Median target $30.00 +276.9%
9 50.0% Strong Buy
8 44.4% Buy
1 5.6% Hold
0 0.0% Sell
0 0.0% Strong Sell

12-Month Price Target

11 analysts · 2026-09-30

Mean target $43.09 +441.3%

← Below all targets Current price $7.96
Low$22.00 Mean$43.09 High$85.00

Peer comparison (GICS sub-industry) Key metrics vs sector peers

22

FY basis, prices as of each company's last fiscal year-end close.

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
IMUX · -0.9 · · · ·
COYA $121M -4.6 123.6% -267.1% -59.5% ·
XGN $139M -6.5 19.7% -30.0% -103.7% 58.3%
BDTX $139M 6.2 · 31.9% 18.3% ·
CADL $310M -7.8 · · -53.7% ·
OKUR · -0.7 · -1733.7% -88.6% ·
ANIX $136M -12.1 0.00% · -62.2% ·

Latest News Recent headlines mentioning this company

23

My Metrics Your personal watchlist — selected rows from Full Fundamentals

26

Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Source: SEC 10-Q filed Aug 11, 2026